Novo Ventures
2020 in review
Novo Ventures

2020 Key Numbers

$570 million invested in the life sciences

<table>
<thead>
<tr>
<th>39 public investments including 9 portfolio company IPOs</th>
<th>33 venture financings including multiple crossover financings and new portfolio companies</th>
<th>Market leader in Europe with 13 transactions</th>
</tr>
</thead>
</table>

$360 million returned

6 new additions to the team

Note: Dollar figures are rounded/calculated based on an average of publicly available monthly DKK/USD exchange rates.
“Novo Ventures had a busy 2020, backing companies that are developing and commercializing products with the potential to significantly advance patient care.

The team’s deep and diverse life science expertise as well as our substantial pool of capital enable us to support a broad range of companies – from early-stage private startups through crossover financings and IPOs to follow-on financings and open market purchases, in both the U.S. and Europe.

In 2021, we will continue to invest heavily in the life sciences and better healthcare.”

Scott Beardsley
Managing Partner, Novo Ventures
## Select crossover and IPO transactions

<table>
<thead>
<tr>
<th>Company</th>
<th>Crossover</th>
<th>IPO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bolt Biotherapeutics</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Edgewise</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Escape Bio</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Preventice</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>VectivBio</td>
<td>✔</td>
<td></td>
</tr>
<tr>
<td>Aligos Therapeutics</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Checkmate Pharmaceuticals</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Eargo</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Freeline Therapeutics</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Praxis Precision Medicines</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Spruce Biosciences</td>
<td>✔</td>
<td>✔</td>
</tr>
<tr>
<td>Acutus Medical</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Akouos</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>CureVac</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Harmony Biosciences</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Inari Medical</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Inozyme Pharma</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Kinnate Biopharma</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Nkarta</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Pulmonx</td>
<td></td>
<td>✔</td>
</tr>
<tr>
<td>Vaxcyte</td>
<td></td>
<td>✔</td>
</tr>
</tbody>
</table>
## Selected new Venture Portfolio companies

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Lava Therapeutics** | Novo Ventures co-led $83m Series C financing  
LAVA Therapeutics is developing a proprietary bispecific antibody platform that engages gamma-delta T cells for the treatment of hematological and solid cancers.  
Based in the Netherlands. |
| **NodThera**    | Novo Ventures led $55m Series B investment  
NodThera is focusing on an exciting new class of anti-inflammatory targets, the NLRP3 inflammasome, with the potential to help patients with many chronic diseases.  
Based in the U.K. |
| **Claris**      | Novo Ventures led $25m Series A financing  
Claris Bio is a privately held biotech company developing a topically administered agent to treat diseases of the cornea.  
Based in the U.S. |
| **Reneo**       | Novo Ventures co-led $95m Series B financing  
Reneo is a clinical stage pharmaceutical company focused on the development of therapies for patients with genetic mitochondrial diseases.  
Based in the U.S. |
Company creation and early-stage collaborations

We selectively enhance our reach in life science hotspots around the world through collaborative relationships.

Red Tree Venture Capital
Red Tree invests in company creation and early-stage opportunities based on the life science innovation coming out of Stanford University and other leading U.S. West Coast institutions.

Broad Institute
Novo Ventures and the Broad Institute of MIT and Harvard have formed a joint initiative to discover and propel new therapies from academic discoveries into the clinic.

BioGeneration Ventures
BioGeneration Ventures (BGV) is a venture capital company with a focus on early-stage European biotech, medtech, and diagnostics companies.
We continued to build our team

Six additions in 2020 bring our team to 28.

Michael K. Bauer, PhD
Venture Partner

Nik Economopoulos, MD
Associate

Nafise Masoumi, PhD
Associate

Joe Markson, PhD
Associate

Ross Castillo, MD
Associate

Danielle Geier, JD
Associate General Counsel
Leadership transition

A special thank you to Thomas Dyrberg for his service and leadership of Novo Ventures as he transitions to a Senior Advisor for our team. Thomas joined Novo Holdings in 2000, helping establish Novo Ventures, for which he has served as a Senior Partner and since 2015 as Managing Partner.

During Thomas’ leadership, Novo Ventures has grown to become among the top biotech venture investors globally. Equally as important, the reputation of Novo Ventures in the life science community is exceptional, living up to the Novo Holdings Way by delivering Performance with Respect and Responsibility.

As of 1 January 2021, the Novo Ventures leadership team consists of:

Scott Beardsley  
Managing Partner

Tiba Aynechi  
Senior Partner

Peter Moldt  
Senior Partner

Naveed Siddiqi  
Senior Partner
The bigger picture

→ Novo Ventures is the ventures arm of Novo Holdings.

→ Established in 1999, Novo Holdings is the investment and asset management company of the Novo Nordisk Foundation.

→ We invest to promote groundbreaking solutions in healthcare and biosustainability — while generating attractive returns that enable the Foundation’s grant-giving activities to support scientific, humanitarian and social causes.

→ The Novo Nordisk Foundation’s vision is to contribute significantly to research and development that improves the lives of people and the sustainability of society.

*Note: Novo Ventures (US) Inc. is a separate legal entity that provides certain consultancy services to Novo Holdings A/S, mainly within the areas of identifying, analysing and negotiating various investment opportunities among life science and biotech companies in the US as well as certain follow-up activities related thereto, such as board memberships, financial control and reporting efforts.*